Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025.
Werewolf Therapeutics, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 27,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 13, 2025 20:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086172 · ownership.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 21:13 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000070 · wk-form4_1717449223.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document |
| May 24, 2024 Filed May 24, 2024 23:46 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0000950170-24-064836 · ownership.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:49 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0000899243-23-016376 · doc4.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-20 F1 · derivative.exercise_date: The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001415889-23-009230 · form4-06052023_040602.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001415889-22-006488 · form4-06132022_040601.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:39 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 7,733 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-22-020980 · doc4.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,733 Underlying: Common Stock · 7,733 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:12 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 23,200 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001785530-21-000047 · wf-form4_163579752074123.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 23,200 shares Expires 2031-10-27 F1 · derivative.exercise_date: The option was granted on October 28, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:13 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $33.36 | $0.00 |
DisclosureSEC source: 0001179110-21-006452 · edgar.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:41 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $62.71 | $0.00 |
DisclosureSEC source: 0001179110-20-012101 · edgar.xml · derivative · entry 1 Chatterjee Meeta · CIK 0001835388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2030-12-16 F1 · derivative.exercise_date: This option was granted on December 17, 2020 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on December 17, 2021 through December 17, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.